Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.35
-$0.44-55.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.60% | 6.09% | -2.53% | -6.23% | -2.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.41% | -32.84% | -26.53% | -27.26% | -22.04% |
| Operating Income | 34.41% | 32.84% | 26.53% | 27.26% | 22.04% |
| Income Before Tax | 33.62% | 31.11% | 24.68% | 27.42% | 23.81% |
| Income Tax Expenses | -3.08% | 102.94% | -19.73% | -18.78% | 15.38% |
| Earnings from Continuing Operations | 33.60% | 31.07% | 24.68% | 27.42% | 23.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.60% | 31.07% | 24.68% | 27.42% | 23.79% |
| EBIT | 34.41% | 32.84% | 26.53% | 27.26% | 22.04% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 62.82% | 57.84% | 50.75% | 50.41% | 45.34% |
| Normalized Basic EPS | 62.83% | 57.87% | 50.75% | 50.41% | 45.35% |
| EPS Diluted | 62.82% | 57.84% | 50.75% | 50.41% | 45.34% |
| Normalized Diluted EPS | 62.83% | 57.87% | 50.75% | 50.41% | 45.35% |
| Average Basic Shares Outstanding | 114.80% | 74.46% | 55.46% | 49.00% | 41.90% |
| Average Diluted Shares Outstanding | 114.80% | 74.46% | 55.46% | 49.00% | 41.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |